BioSpace News Archive

NextSense, the foundation of brain health, came out of stealth with an announcement made from the AES (American Epilepsy Society) Annual Meeting in Chicago, where NextSense and its partners are presenting the results of their research on seizure detection to peers in academia and industry for the first time.

Marinus Pharmaceuticals, Inc. today announced new clinical trial and research data being presented at the American Epilepsy Society (AES) Annual Meeting in Chicago, Illinois.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), today responded to data published from the COV-Boost COVID-19 vaccine trial, which investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines at different dose levels when administered as a third dose, or booster, to people primed with either Pfizer’s Comirnaty or AstraZeneca’s Vaxzevria.

ClaroNav, a leader in surgical navigation systems with a strong track record of growth and innovation, is pleased to announce that its CKI subsidiary has received Health Canada approval for its Navient ENT and Navient Cranial as Class III medical devices.

Today, the Honourable Filomena Tassi, Minister of Public Services and Procurement, announced that the Government of Canada has signed agreements with Merck and Pfizer for access to their COVID-19 oral antiviral treatments.

Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) , announced today that the U.S. Food and Drug Administration (FDA) denied a request from the company to adjust the analysis of the pivotal AGENT study’s secondary endpoint of progression-free survival (PFS).

MEI Pharma, Inc. today announced the grant of inducement stock options for an aggregate of 166,000 shares of the company’s common stock to six new employees.

Atara Biotherapeutics, Inc. today reported the grant of an aggregate of 21,438 restricted stock units of Atara’s common stock to seven newly hired employees and stock options to purchase an aggregate of 24,017 shares.

AbCellera (Nasdaq: ABCL) today announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include pediatric patients under the age of 12.